ZYUS — Zyus Life Sciences Balance Sheet
0.000.00%
- CA$56.57m
- CA$68.32m
- CA$0.48m
Annual balance sheet for Zyus Life Sciences, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 8.45 | 8.59 | 0.212 | 5.85 | 1.9 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.059 | 0.044 | 0.243 | 0.627 | 0.366 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 8.51 | 8.64 | 6.27 | 9.39 | 3.36 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0 | 0 | 17 | 13.9 | 11.2 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 8.51 | 8.64 | 64.7 | 41.6 | 14.7 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Current Liabilities | 0.319 | 0.096 | 14.3 | 13.2 | 17.4 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 0.319 | 0.096 | 60 | 18.5 | 20 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 8.19 | 8.54 | 4.74 | 23.1 | -5.34 |
Total Liabilities & Shareholders' Equity | 8.51 | 8.64 | 64.7 | 41.6 | 14.7 |
Total Common Shares Outstanding |